Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126078215 | 12607821 | 5 | F | 2008 | 20160915 | 20160729 | 20160916 | EXP | US-JNJFOC-20090304320 | JANSSEN | 0.00 | A | M | Y | 116.58000 | KG | 20160916 | CN | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126078215 | 12607821 | 1 | SS | RISPERDAL | RISPERIDONE | 1 | Oral | N | N | UNKNOWN;UNKNOWN | 0 | 6 | MG | TABLETS | |||||
126078215 | 12607821 | 2 | PS | RISPERDAL | RISPERIDONE | 1 | Oral | 1 MG TO 3 MG | N | N | UNKNOWN;UNKNOWN | 20272 | 3 | MG | TABLETS | QD | |||
126078215 | 12607821 | 3 | SS | RISPERDAL CONSTA | RISPERIDONE | 1 | Intramuscular | N | N | UNKNOWN | 21346 | 50 | MG | MICROSPHERES | QOW | ||||
126078215 | 12607821 | 4 | SS | INVEGA SUSTENNA | PALIPERIDONE PALMITATE | 1 | Intramuscular | INITIAL DOSE FOLLOWED BY 2 INJECTIONS OF 156 MG | N | N | UNKNOWN | 22264 | INJECTION | ||||||
126078215 | 12607821 | 5 | SS | INVEGA | PALIPERIDONE | 1 | Oral | N | N | UNKNOWN | 21999 | TABLETS | |||||||
126078215 | 12607821 | 6 | SS | HALOPERIDOL. | HALOPERIDOL | 1 | Unknown | N | UNKNOWN | 15923 | UNSPECIFIED | ||||||||
126078215 | 12607821 | 7 | SS | SEROQUEL | QUETIAPINE FUMARATE | 1 | Oral | 50 MG TO 200 MG | U | 0 | TABLETS | ||||||||
126078215 | 12607821 | 8 | C | LEXAPRO | ESCITALOPRAM OXALATE | 1 | Oral | D | 0 | 20 | MG | UNSPECIFIED | QD | ||||||
126078215 | 12607821 | 9 | C | TOPAMAX | TOPIRAMATE | 1 | Unknown | D | 0 | UNSPECIFIED | |||||||||
126078215 | 12607821 | 10 | C | VITAMIN | VITAMINS | 1 | Unknown | D | 0 | UNSPECIFIED | |||||||||
126078215 | 12607821 | 11 | C | TRILEPTAL | OXCARBAZEPINE | 1 | Unknown | D | 0 | UNSPECIFIED |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
126078215 | 12607821 | 1 | Schizoaffective disorder |
126078215 | 12607821 | 2 | Schizoaffective disorder |
126078215 | 12607821 | 3 | Schizoaffective disorder |
126078215 | 12607821 | 4 | Schizoaffective disorder |
126078215 | 12607821 | 5 | Schizoaffective disorder |
126078215 | 12607821 | 6 | Schizoaffective disorder |
126078215 | 12607821 | 7 | Schizophrenia |
126078215 | 12607821 | 8 | Depression |
126078215 | 12607821 | 9 | Drug therapy |
126078215 | 12607821 | 10 | Vitamin supplementation |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
126078215 | 12607821 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126078215 | 12607821 | Blood cholesterol increased | |
126078215 | 12607821 | Drug effect decreased | |
126078215 | 12607821 | Drug ineffective | |
126078215 | 12607821 | Drug intolerance | |
126078215 | 12607821 | Hyperphagia | |
126078215 | 12607821 | Psychotic disorder | |
126078215 | 12607821 | Schizoaffective disorder | |
126078215 | 12607821 | Weight increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
126078215 | 12607821 | 1 | 200805 | 0 | ||
126078215 | 12607821 | 2 | 200805 | 0 | ||
126078215 | 12607821 | 3 | 200805 | 0 | ||
126078215 | 12607821 | 4 | 20160601 | 201607 | 0 | |
126078215 | 12607821 | 5 | 201605 | 201607 | 0 | |
126078215 | 12607821 | 6 | 201607 | 0 | ||
126078215 | 12607821 | 7 | 200805 | 0 | ||
126078215 | 12607821 | 8 | 200805 | 0 | ||
126078215 | 12607821 | 9 | 2004 | 0 |